cancer

FDA slams cancer drugs Spectrum and Oncopeptides over efficacy concerns ahead of ODAC meeting

FDA slams cancer drugs Spectrum and Oncopeptides over efficacy concerns ahead of ODAC meeting

Thursday’s meeting of the FDA’s Oncology Drug Advisory Committee is likely to be a massacre for two biopharmaceutical companies, Spectrum Pharmaceuticals and Oncopeptides, as reviewers today raised important concerns and questions for both sponsors in papers. information published before the meeting. Spectrum is seeking approval for poziotinib tablets as a treatment for patients with previously …

FDA slams cancer drugs Spectrum and Oncopeptides over efficacy concerns ahead of ODAC meeting Read More »

J&J tried to block the lawsuits of 40,000 cancer patients.  Court wants answers

J&J tried to block the lawsuits of 40,000 cancer patients. Court wants answers

A bottle of Johnson & Johnson baby powder is displayed on a table. J&J pulled its iconic Johnson baby powder from shelves in the United States in 2020. Justin Sullivan/Getty Images hide caption toggle caption Justin Sullivan/Getty Images A bottle of Johnson & Johnson baby powder is displayed on a table. J&J pulled its iconic …

J&J tried to block the lawsuits of 40,000 cancer patients. Court wants answers Read More »